We are live on ! Find out more
IRD

Opus Genetics
IRD

35 hedge funds and large institutions have $6.57M invested in Opus Genetics in 2014 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 8

0% more funds holding

Funds holding: 35 → 35 (0)

0% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 9

49% less capital invested

Capital invested by funds: $12.9M → $6.57M (-$6.35M)

Holders
35
Holders Change
–
Holders Change %
0%
% of All Funds
1.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
11
Reduced
8
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$829K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$196K
3
CCM
Condor Capital Management
New Jersey
+$109K
4
Deutsche Bank
Deutsche Bank
Germany
+$96.8K
5
Bank of New York Mellon
Bank of New York Mellon
New York
+$82.3K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$2.29M
2
SFM
Sphera Funds Management
Israel
-$2.17M
3
PAM
Panagora Asset Management
Massachusetts
-$354K
4
BG
BlackRock Group
United Kingdom
-$340K
5
U
UBS
Switzerland
-$315K
Name Holding Trade Value Shares
Change 		Change in
Stake
LTFS
26
Ladenburg Thalmann Financial Services
Florida
$15K +$16.4K +36 New
FNYS
27
First New York Securities
New York
$13.1K +$4.55K +10 +48%
Citigroup
28
Citigroup
New York
$11K -$1.82K -4 -13%
CS
29
Credit Suisse
Switzerland
$10K -$189K -415 -95%
Fisher Asset Management
30
Fisher Asset Management
Washington
$9K +$9.55K +21 New
Canada Life
31
Canada Life
Manitoba, Canada
$8K +$5K +11 +183%
TRCT
32
Tower Research Capital (TRC)
New York
$4K +$2.27K +5 +100%
Royal Bank of Canada
33
Royal Bank of Canada
Ontario, Canada
$2K +$1.82K +4 New
CP
34
Corbenic Partners
Pennsylvania
$1K – – –
Ameriprise
35
Ameriprise
Minnesota
$1K +$1.36K +3 New
Millennium Management
36
Millennium Management
New York
– -$2.29M -4,412 Closed
SFM
37
Sphera Funds Management
Israel
– -$2.17M -4,180 Closed
PAM
38
Panagora Asset Management
Massachusetts
– -$354K -683 Closed
BG
39
BlackRock Group
United Kingdom
– -$340K -657 Closed
JP Morgan Chase
40
JP Morgan Chase
New York
– -$88K -169 Closed
RCM
41
Rotella Capital Management
Washington
– -$46K -89 Closed
CAS
42
CTC Alternative Strategies
Illinois
– -$34.8K -67 Closed
BIT
43
BlackRock Institutional Trust
California
– -$34K -65 Closed
AGM
44
Alpine Global Management
New York
– -$22K -42 Closed
1
2

IRD Hedge Fund Activity: Q2 2014 in Review

35 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q2 2014, worth a combined $6.57M — down 49% from $12.9M a quarter earlier.

Fund positioning in IRD was balanced in Q2 2014: 9 funds opened new positions, 9 closed out, 11 added to existing stakes and 8 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $829K. The largest seller was Millennium Management, exiting entirely with an estimated $2.29M sold.

  • 35 institutional investors held Opus Genetics (IRD) as of Q2 2014, unchanged from Q1 2014.
  • Funds reported $6.57M of Opus Genetics stock for Q2 2014, down 49% quarter-over-quarter.
  • 9 funds opened new Opus Genetics positions in Q2 2014 and 9 closed out, a net change of 0 holders.
  • The largest Opus Genetics buyer in Q2 2014 was Morgan Stanley, an estimated $829K added.
  • The largest Opus Genetics seller in Q2 2014 was Millennium Management, an estimated $2.29M sold.

Based on aggregated 13F filings for Q2 2014.